(Total Views: 731)
Posted On: 09/07/2025 4:04:10 PM
Post# of 156742
brentie, thanks for the post and the links. The NY Times article does not mention Leronlimab but it mentions Maraviroc. Here are a couple of the quotes:
If you look in the comments, Steve from Lawrenceville, NJ posted this comment on 9/4:
Quote:
But no one had looked at what Maraviroc might be doing in the brain. In 2019, Dr. Carmichael laid out three lines of evidence showing that Maraviroc boosted neuroplasticity after brain injury, and published his findings in a landmark paper in the journal Cell.
Maraviroc is not a perfect drug, Dr. Carmichael said. It does cross the blood-brain barrier, but only in limited amounts. That’s why his allegiance is not to one drug, but to laying the groundwork for future therapies by deepening the understanding of the brain’s recovery systems.
If you look in the comments, Steve from Lawrenceville, NJ posted this comment on 9/4:
Quote:
There is another CCR5 blocking drug that's even more effective, with fewer side effects... none of them serious.
It's called Leronlimab, made by Cytodyn.
The CCR5 receptor plays a vital role in governing the immune system's response to a wide range of disease processes.
Go to Cytodyn's website to learn more about it.
(16)
(0)
